These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18094427)

  • 1. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
    Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
    Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
    Balin-Gauthier D; Delord JP; Pillaire MJ; Rochaix P; Hoffman JS; Bugat R; Cazaux C; Canal P; Allal BC
    Br J Cancer; 2008 Jan; 98(1):120-8. PubMed ID: 18182978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
    J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
    Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
    Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in combination therapy: from bench to clinic.
    Gerber DE; Choy H
    Cancer Metastasis Rev; 2010 Mar; 29(1):171-80. PubMed ID: 20140759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
    Moosmann N; Heinemann V
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
    Chong G; Cunningham D
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
    Ekblad L; Johnsson A
    Anticancer Res; 2012 Mar; 32(3):783-6. PubMed ID: 22399593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
    Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
    Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.